Akero Therapeutics, Inc. has announced initial topline results for the 96-week timeframe from the HARMONY study, a Phase 2b trial. The trial is designed to assess the effectiveness and safety of Akero's principal product, efruxifermin, in patients with pre-cirrhotic metabolic dysfunction-associated steatohepatitis (fibrosis stage 2 or 3).
Akero stated that patients treated with efruxifermin displayed significant improvements across almost all histological endpoints according to the ITT analysis, and in the primary analysis of patients with biopsies taken at week 96.
Andrew Cheng, the CEO of Akero, stated that the results reveal the potential for continued fibrosis improvement and an increased span of anti-fibrotic treatments responses across treated patient populations through prolonged exposure to efruxifermin.
For further health-related news, visit the rttnews.com portal.
